--- title: 'Industry Daily Summary: What Happened on October 12, 2026' headline: argenx sets 2030 pipeline goals after $2.2 billion Forte deal description: Perceptive Discovery and Nucleus RadioPharma linked research with manufacturing, while Datavant agreed to a minority investment. url: https://thebench.bio/news/industry/2026-10-12 topic: industry date: '2026-10-12' covers: - '2026-10-12' date_published: '2026-10-12T12:03:26Z' date_modified: '2026-10-12T12:03:26Z' tags: - Industry - Software sources: 3 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on October 12, 2026 **argenx sets 2030 pipeline goals after $2.2 billion Forte deal** Perceptive Discovery and Nucleus RadioPharma linked research with manufacturing, while Datavant agreed to a minority investment. ## Today in brief argenx CEO Karen Massey set a 2030 goal of treating 50,000 patients across 10 diseases and advancing five molecules into late-stage development. [1] She also described new treatment formats and programs added through the Forte Biosciences acquisition. [1] ## argenx sets a 2030 target for patients and late-stage drugs argenx acquired Forte Biosciences earlier in 2026 for $2.2 billion. [1] CEO Karen Massey said the company aims to treat 50,000 patients across 10 diseases and have five molecules in late-stage development by 2030. [1] Massey said three additional treatment formats could reach the market within a few years: a doctor-delivered injection under the skin, a prefilled syringe and an autoinjector. [1] She said argenx is also developing an oral FcRn molecule. [1] Massey said argenx is developing empasiprubart for multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy, and studying it in combination therapy for myasthenia gravis. [1] She expects topline results from the Phase 3 multifocal motor neuropathy study in the fourth quarter of 2026. [1] Massey said argenx is advancing adimanebart for congenital myasthenic syndromes and other neuromuscular conditions, including spinal muscular atrophy. [1] Forte's lead candidate, FB102, is being tested in vitiligo and celiac disease and could address multiple autoimmune conditions, she said. [1] ## Also worth knowing - Perceptive Discovery and Nucleus RadioPharma formed a non-exclusive partnership connecting preclinical imaging with clinical and commercial manufacturing for radiopharmaceutical programs. [2] - Investment funds managed by Neuberger and KKR agreed to acquire a significant minority stake in Datavant. New Mountain Capital will retain control. [3] ## The day in numbers - **$2.2 billion**: argenx's purchase price for Forte Biosciences earlier in 2026 [1] - **50,000 patients across 10 diseases**: argenx's treatment ambition, as stated by CEO Karen Massey [1] - **5 molecules by 2030**: argenx's target for late-stage development [1] ## Also published - [Medtech's digital experience is ready for an upgrade](), pharmaphorum - [Aicuris acquisition delivers new drug for Asahi Kasei](), pharmaphorum - [Notable TechBio startups and companies operating in Malaysia 🇲🇾](), MetaphysicalCells ## Sources 1. [What’s next for argenx, Europe’s autoimmune breakthrough?](), European Biotechnology, 2026-10-12 2. [Perceptive, Nucleus partner to support radiopharmaceutical development](), Pharmaceutical Technology, 2026-10-12 3. [Your Weekly TechBio News ▶️](), MetaphysicalCells, 2026-10-12 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: